Αρχική World News FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E... World News FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF V600E Mutation Από Ogkologos - 11 Μαρτίου, 2026 443 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ΚΑΡΚΙΝΟΣ ΣΤΟΜΑΧΟΥ 7 Φεβρουαρίου, 2019 AI is impacting cancer care, but also the environment 25 Σεπτεμβρίου, 2025 Presence of Intratumoural TLSs in Advanced STS as a Potential Predictive... 7 Ιουνίου, 2022 ESMO Gastrointestinal Cancers Congress 2024 Munich, Germany, 26-29 June 14 Ιουνίου, 2024 Φόρτωση περισσοτέρων HOT NEWS NF1 Associated with More Cancer Types Than Previously Known FDA Approves Irinotecan Liposome for First-Line Treatment of Metastatic Pancreatic Adenocarcinoma Proton and Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer Show Similar Late Effects, QoL,... Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated,...